Monopar Therapeutics (MNPR) Net Cash Flow (2017 - 2025)
Monopar Therapeutics (MNPR) posted Net Cash Flow of -$65.9 million for Q4 2025, down 174.79% sequentially from $88.2 million in Q3 2025, and down 265.69% YoY from $39.8 million in Q4 2024.
Monopar Therapeutics (MNPR) Net Cash Flow (2017 - 2025) Analysis & Trends
Monopar Therapeutics has reported Net Cash Flow for 9 years, with the latest figure at -$65.9 million in Q4 2025.
- Quarterly Net Cash Flow fell 265.69% year-over-year to -$65.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $15.9 million (down 58.7% YoY) and the FY2025 annual result came in at $15.9 million, down 58.7% from the prior year.
- Net Cash Flow retreated to -$65.9 million in Q4 2025 per MNPR's latest filing, from $88.2 million in the prior quarter.
- Over five years, Net Cash Flow peaked at $88.2 million in Q3 2025 and troughed at -$65.9 million in Q4 2025.
- A 5-year average of $2.3 million and a median of -$1.6 million in 2021 frame the typical range for Net Cash Flow.
- The sharpest annual moves came in 2021 and 2025: Net Cash Flow tumbled 2814.45% in 2021, then surged 84636.59% in 2025.
- Over 5 years, Net Cash Flow stood at -$2.0 million in 2021, then tumbled by 198.16% to -$6.1 million in 2022, then jumped by 128.92% to $1.8 million in 2023, then soared by 2162.54% to $39.8 million in 2024, then sank by 265.69% to -$65.9 million in 2025.
- According to Business Quant data, Net Cash Flow over the past three periods registered -$65.9 million, $88.2 million, and -$206922.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Monopar Therapeutics | 965.64 Mn | 912.88 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -65.94 Mn |
| Dec 31, 2025 | -65.94 Mn |
| Sep 30, 2025 | 88.18 Mn |
| Sep 30, 2025 | 88.18 Mn |
| Jun 30, 2025 | -206,922.00 |
| Jun 30, 2025 | -206,922.00 |
| Mar 31, 2025 | -6.10 Mn |
| Mar 31, 2025 | -6.10 Mn |
| Dec 31, 2024 | 39.80 Mn |
| Dec 31, 2024 | 39.80 Mn |
| Sep 30, 2024 | -104,304.00 |
| Sep 30, 2024 | -104,304.00 |
| Jun 30, 2024 | -1.69 Mn |
| Jun 30, 2024 | -1.69 Mn |
| Mar 31, 2024 | 543,151.00 |
| Mar 31, 2024 | 543,151.00 |
| Dec 31, 2023 | 1.76 Mn |
| Dec 31, 2023 | 1.76 Mn |
| Sep 30, 2023 | -1.71 Mn |
| Sep 30, 2023 | -1.71 Mn |